# A German Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Type 2 Diabetes Patients.

Study · id `cardio:ct-nct02268929` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02268929](<https://clinicaltrials.gov/study/NCT02268929>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02268929

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 414 participants.

## Technical summary

Registry record NCT02268929. Randomized; no masking; primary purpose diagnostic. Start 2014-10-14 (actual); primary completion 2017-01-11 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose diagnostic
- Phase: Not applicable
- Enrolled: 414 participants (enrolled count; ClinicalTrials.gov record NCT02268929, source copy `cardio:ctgov-nct02268929-2017-11-24`, retrieved 2026-10-26)
- Started: 2014-10-14 (actual) (ClinicalTrials.gov record NCT02268929, source copy `cardio:ctgov-nct02268929-2017-11-24`, retrieved 2026-10-26)
- Primary completion: 2017-01-11 (actual) (ClinicalTrials.gov record NCT02268929, source copy `cardio:ctgov-nct02268929-2017-11-24`, retrieved 2026-10-26)
- Completion: 2017-02-09 (actual) (ClinicalTrials.gov record NCT02268929, source copy `cardio:ctgov-nct02268929-2017-11-24`, retrieved 2026-10-26)
- Countries: Germany (ClinicalTrials.gov record NCT02268929, source copy `cardio:ctgov-nct02268929-2017-11-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02268929-2017-11-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: A German Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Type 2 Diabetes Patients.
- Acronym: PDM-ProValueGP
- Condition: Diabetes Mellitus, Type 2
- Intervention (Device): Accu-Chek Smart Pix Software
- Intervention (Device): Accu-Chek Smart Pix readout Device
- Lead sponsor: Hoffmann-La Roche
- Lead sponsor class: INDUSTRY
- Collaborator: Roche Diabetes Care
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Hoffmann-La Roche (`cardio:org-hoffmann-la-roche`)
- Registry lists this organization as a collaborator: Roche Diabetes Care (`cardio:org-roche-diabetes-care`)

## Provenance

Content hash: 4e97994afd71e8a318d89216cee01c6bc25a818cddec659393f63e0e39c4c1d5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
